Contract notice: Pharmaceutical products Tender, Germany - 27027000

Procurement Summary

Country : Germany

Summary : Contract notice: Pharmaceutical products

Deadline : 05 Sep 2020

Other Information

Notice Type : Tender

TOT Ref.No.: 27027000

Document Ref. No. : 413548-2018

Competition : ICB

Financier : Self Financed

Purchaser Ownership : -

Tender Value : Refer Document

Purchaser's Detail

Purchaser : DAK-GESUNDHEIT
Office Name: DAK-Gesundheit
Address: Nagelsweg 27-31
Town: Hamburg
Postal Code: 20097


Phone: +49 402396-2682
Fax: +49 402396-3661
Germany
Email :vergabestelle@dak.de
URL :www.dak.de

Tender Details

Object of the contract
Pharmaceutical products

Description: Contract notice: Pharmaceutical products

Authority Type: Body governed by public law
Contact Nature: Supplies
Procedure: Open procedure
Document: Contract notice
Regulation: European Union
Award criteria: Lowest price
CPV code: 33600000, 33600000
CPV Description: Pharmaceutical products.

Conclusion of a non-exclusive discount agreement pursuant to Section 130a (8) SGB V on the active substance dalteparin, ATC B01AB04, for the period 1.11.2018 31.10.2020 - Reference Number: 1002305 - Dalteparin, ATC B01AB04

- 130a Abs. 8 SGB V allows the health insurance companies and pharmaceutical companies, framework discount contracts on the payable to the statutory health insurance companiesn to close medicines. In view of the pertinent statutory provisions on the awarding of public contracts, a regular process of active substance-based, public procurement procedures takes place in accordance with the regulations of the 4th part of the GWB by the DAK-G. For the medicinal product to be designated by the tenderer in Annex 2 to the contract for the active substance dalteparin, ATC B01AB04, DAK-G intends to conclude drug discount agreements with as many pharmaceutical companies as possible until the entry into force of new drug rebates. A discount contract within the scope of the approval model for the o.g. Active ingredient will enter into force on 1.11.2018 and will end on 31.10.2020. It ends automatically regardless of the entry into force of the exclusive trustDAK-Gesundheit assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory accessibility of all pharmaceutical companies. Irrespective of this, it automatically ends with the entry into force of the exclusive contract for Dalteparin, ATC B01AB04, as a result of a formal Vprocedure according to the regulations of the 4th part of the GWB with one or more contractual partners. In order to cope with the diversity of potential contractors under the authorization model, each pharmaceutical company will be able to conclude a framework contract at any time and under the same conditions during the contract period. The contract required for thiscan be obtained via the online portal www.dtvp.de/center under the subsection I.3. The following link is available for download.

Prerequisites for the conclusion or later accession to the contracts that enter into force on 1.11.2018 are the complete and timely transmission of the following documents / declarations / attachments (available for download under I). 3. mentioned link) to the following contact person at DAK-Gesundheit:

1) Letter of Request

2) Current Proof of Registration in the Professional or Commercial Register (see III.1.1.)

3) Self-declaration by the company (Annex A1) that None of the exclusion criteria according to -- 123, 124 GWB is present (see III.1.1.). 4) Self-declaration that for those medicines for which the interestnt would like to conclude a contract in the context of this procedure, that there is a drug license and that the bidder is entitled to distribution at the beginning of the contract (Appendix A2) (see III.1.1.)

5) Self-declaration by the company that the statutory minimum wage requirements and adhered to the rate of loyalty (Annex A3) (see III.1.1.).

6) Recognition of the contractualn DAK health conditions, in particular the prescribed rebates by signing the contract stamped with a company stamp (twice original) by the interested party at the designated place.

7) Completed Annexes 1 and 2 to the contract (2- fold in the original). The interested party has here the medicines to the o.g. Enter active substance, which would be subject of the contract

8) Effective pre-qualification notification of DAK health (see III.1.1 and III.1.2.)

The documents must be submitted by post to:

DAK Health

Henri Affinass (0032 50)

Nagelsweg 27 -31

20097 Hamburg

Furthermore, the attachment 2 as an Excel file at the same time to the mail address am_rabattvertraege@dak.de to send. Contracts under this model and o.g. Become an active ingredientcompleted for the first time with effect from 1.11.2018 and will end on 31.10.2020. Interested parties who wish to become partners at this time have the o.g., documents to be submitted by the 5th of the previous month at o.g. Submit job. It depends on the timely access to the DAK-health. Later accessions are possible at any time. To during the term of the contract forThe 1st or 15th of the following month, the o.g. Documents, regardless of the desired accession, the DAK-health until the 5th of the previous month. Again, it depends on the timely access to DAK-health. Example: The bidder wished to join the club should take place on 15.07.20xx (following month), the documents would have to be submitted until 5.6.20xx (previous month)

Note: The publication is done here using the Open Procedure form. As has already been made clear, this is not one - the notice had to be used for technical reasons, as there is no form suitable for authorization procedures.

1) Current proof of registration in the professional or commercial register (not olderthan 6 months in case of dispatch) in accordance with the legislation of the country in which the company is established, eg current commercial register extract; Copy is sufficient.

2) Self-declaration of the company that none of the exclusion criteria according to -- 123, 124 GWB exists. Attachment A1 must be signed, stamped with the company and submitted in the original.

3) EigenerklaerNotification that, for those medicinal products for which the interested party wishes to conclude a contract under this procedure, there is a marketing authorization and that the tenderer is entitled to sell at the inception of the contract (Appendix A2) (see III.1.1.) ) Self-declaration of the company, that the legal requirements for the minimum wage and the tariff fidelity observed and acceptedold ones (Annex A3). Attachment A3 has to be signed, accompanied by company stamp and submitted in original form.

DAK-Gesundheit has published a so-called pre-qualification procedure for pharmaceutical companies for the simplified participation in future drug rebate tenders via the European Announcement Platform (EU-Announcement 2015 / S 105- 190319 of 3.6.2015). If the bidder has received an effective pre-qualification notification from DAK-Gesundheit in good time before submission of the documents, he needs the company-specific proof of eligibility (proof of entry in the trade or professional register, self-declaration by the company that none of the exclusion criteria according to -- 123, 124 GWB is present, certificate of safetynotice of the statutory health insurance) with reference to and addition of the Praequalifikationsbescheides in copy no longer be attached. Attachment A2 must always be attached. Accordingly, the DAK health pre-qualification notification also serves as proof of DAK health open-house procedures, irrespective of the value of the order.

Self-declaration that for those drugs, -for which the prospective customer wishes to conclude the contract in the context of this procedure, a drug license exists and that the bidder is entitled to the distribution at the beginning of the contract. Attachment A2 must be signed, provided with the company stamp and submitted in the original. DAK-Gesundheit has a so-called pre-qualification via the European announcement platformpublished for pharmaceutical companies for simplified participation in future drug rebate tenders (EU 2015 / S 105-190319 of 3.6.2015). If the bidder has received an effective pre-qualification notification from DAK-Gesundheit in good time before submission of the documents, he needs the company-specific proof of suitability (proof-the entry in the professional or commercial register, self-declaration of the company that none of the exclusion criteria acc. -- 123, 124 GWB is present, certificate of health insurance from the statutory health insurance) with reference and enclosing the Praequalifikationsbescheides in copy no longer to be enclosed. Attachment A2 must always be attached. The Praequalifikationsbescheid the DAK GesunAccordingly, dheit also serves as proof in open house procedures of DAK-Gesundheit.

The tender documents can also be sent by e-mail in the case of IAB. be requested. The tender documents will then be sent by e-mail. Questions and information on the tender documents are available electronically (by means of bidder communication via the Vdelivery portal www.dtvp.de) or in necessary individual cases by e-mail or in writing (by fax or letter) to those under I.1. to be addressed. They are to be formulated in German. Answers will be made available to all entrepreneurs who have requested the tender documents by means of a registration in anonymous form. This will be the answersto the entrepreneurs by means of bidder communication via the allocation portal www.dtvp.de. Companies who have downloaded the tender documents without registration have to take responsibility for further communication and, if necessary, to the above mentioned. Contact point.

This publication is not a contract awards public procurement contract under the 2014/24 EU Joint Programming Council / procurement contract. In order to ensure the widest possible degree of transparency for the envisaged contracts, it will be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form-the contract notice will be used. The resulting conceptual requirements, such as the procedure "open procedure", are solely due to the use of this announcement form and the publication platform.Another meaning, in particular a submission to public procurement regulations, is not mandatory for legal reasonsare not related.

Notice ID: CXP4YM5YJ2N


Internet address (URL): www.dak.de

Documents

 Tender Notice